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Aim: The article presents the results of developing the composition and technology of obtaining the liposomal form of docetaxel. 
The effect of the phospholipid composition of the membrane, ionic strength, pH, temperature, cryoprotectant type, and other factors 
on the stability of liposomes and the docetaxel incorporation has been considered. Results: Reduction of toxicity of the liposomal form 
of docetaxel (LD50 — 137 ± 7.7 mg/kg) was found in comparison with its free form (LD50 — 101 ± 6.3 mg/kg). Preservation of nanosize 
particle after lyophilization has been shown. Conclusions: As a result of the studies, the optimal composition and technological scheme 
for obtaining liposomes containing docetaxel have been developed allowing large-scale production of docetaxel in liposomal form.
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The taxanes� in partic�lar docetaxel �Doc�� are 
widely �sed as chemotherapy agents for treatment 
of breast� ovarian� prostate� stomach� non-small cell 
l�ng cancers� sq�amo�s cell carcinoma of the head 
and neck. Doc �C4�H5�NO�4� is a semisynthetic dr�g 
prod�ced by chemical modification of the s�bstance 
extracted from the needles of the E�ropean yew. A wide 
spectr�m of antit�mor activity is determined by the 
�niq�e mechanism of Doc action. The dr�g facilitates 
acc�m�lation of t�b�lin in intracell�lar str�ct�res — mi-
crot�b�les and prevents their breakdown� which leads 
to abnormality of mitosis and interphase processes 
in t�mor cells [�]. Moreover� Doc exhibits activity against 
some cells� prod�cing an excess of P-glycoprotein [�]� 
which is encoded by the gene of m�ltidr�g resistance. 
Doc is effective for treatment of metastatic cancer 
as the second line of chemotherapy for most solid t�-
mors [�]. At present� Doc is intensively st�died in com-
bined chemotherapy with other antit�mor dr�gs incl�d-
ing monoclonal antibodies [4� 5]. At the same time� 
Doc is known to ca�se cardiac toxicity� dermatological 
toxicity� chronic fatig�e syndrome� m�cositis� allergic 
reactions� peripheral ne�ropathy. Also patients treated 
with Doc often experience febrile ne�tropenia� which 
req�ires �rgent hospitalization [6].
One of the most important trends in modern 
pharmace�tical technologies consists in designing 
targeted therape�tic systems. Nanosomal carriers 
of dr�gs aimed at increasing the target effects as well 
as bioavailability of cytotoxic dr�gs are s�ccessf�lly 
�sed [���4]. In recent years� there have been reports 
of Doc incorporation into nanoparticles of vario�s 
polymer carriers� pegylated particles and liposomes 
�Lip� of nat�ral and synthesized lipids [��� �����].
Bearing in mind that the bioavailability and stability 
of pharmace�tical preparations depends to a great extent 
on the sol�bility of the active agent� the aim of o�r st�dy 
is to create a sol�ble form of Doc incorporated in Lip. The 
report s�mmarizes o�r data on the properties of Lip-Doc 
obtained at a different ratio of lipid components forming 
nanoparticles. We have analyzed stability of s�ch prepa-
rations� Doc incorporation and their toxicity.
MATERIALS AND METHODS
Lipid substances. We �sed nat�ral phospholi pids 
�Ph�: phosphatidylcholines �PC� from egg yolks �Bi-
olek� Kharkiv� Ukraine� or LIPOID E PC S �Lipoid GmbH� 
Germany� of �6% p�rity �imp�rities: phosphatidyl eth-
anolamine not more than �NMT� �.�%� Lyso PC NMT 
�.�%� sphingomyelin NMT �.�%�; dyphosphatidylg-
lycerol �DPHG� from bovine cardiac m�scle �Biolec� 
of ��% p�rity �imp�rities: phosphatidyl ethanolamine 
NMT �.5%� PC NMT 6.�%� sphingomyelin and phos-
phatidylserine NMT �%�. The oxidation degree of fatty 
acids was determined from the oxidation index val�e 
meas�red as a ratio of optical densities at ��5 nm and 
��� nm in ethanol. Oxidation index of lipids �sed was: 
PC — NMT �.�; DPHG — NMT �.�.
Preparation of Lip. Lip were prepared according 
to the technology that we developed earlier [��]. To dis-
trib�te evenly the components of the lipid film� Doc was 
dissolved in an organic solvent containing Ph in a certain 
ratio and concentration. The solvent was completely 
removed on a rotary vac��m evaporator at a tempera-
t�re of �8�4� °C and then the solvent resid�es were 
evaporated in a stream of nitrogen. The res�lting thin lipid 
film was hydrogenated in an aq�eo�s lactose sol�tion 
in a heated bath at a temperat�re of 4��4� °C to obtain 
a homogeneo�s s�spension. The res�lting s�spen-
sion was either �ltrasonicated for ����5 min depend-
ing on the temperat�re of the transition phase of the 
lipids� or extr�ded thro�gh a two-layer polycarbonate 
�.� μm filter to obtain Lip of �niform size. Homogeniza-
tion was also carried o�t by extr�sion on a homogenizer 
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Microfl�ids-��� at a preset press�re [��]. The em�lsion 
was sterilized by filtration ��.8��.�� μm�� po�red into 
vials and freeze-dried followed by filling with an inert 
gas. As cryoprotectants� we �sed lactose �or trehalose� 
at vario�s ratios Ph:cryoprotectant ��:�� �:�� �:�� �:4�. 
The process of Lip s�blimation consists of two stages. 
First� we remove free water �p to 8��85%� at a constant 
rate of drying �this stage takes 4��5�% of overall time�. 
At the second stage� we remove �p to �5��8% of bo�nd 
water �those integrated in Lip str�ct�re�. The res�lt-
ing sterile lyophilized Lip-Doc samples were dissolved 
in a sterile aq�eo�s solvent. The composition obtained 
appeared like a homogeno�s white em�lsion.
Analytical methods. Lip size was meas�red 
by photon correlation spectroscopy on nanosizer 
Shimadz� SALD-���� �sing a semicond�ctor la-
ser at a wavelength of ��5 nm and a temperat�re 
of �� °C. The content of Doc and imp�rities in the samples 
of composition was assayed by high performance 
liq�id chromatography �HPLC�. The Agilent ���� chro-
matograph was �sed with a chromatographic col�mn 
�5� × 4.6 mm filled with Zorbax SB-CIS sorbent with 
a particle size of �.5 μm �«Hewlett Packard»�; a mobile 
phase was methanol:acetonitrile:water ��6:��:���; 
the flow rate was � ml/min; detection at a wavelength 
of ��� μm; the detection time �8� min; the col�mn tem-
perat�re was �8 °C. Thin layer chromatography was car-
ried o�t on Sil�fol plates in chloroform:methanol:water 
�65:�5:4�. To identify Ph� we �sed standard Ph samples 
from «Sigma». The oxidation index was determined 
by UV-spectroscopy at two wavelengths: ��� nm and 
��5 nm.
Toxicity in vivo. We �sed Balb/c mice weighing 
�8��� g. The dr�gs were administered intraveno�sly 
twice daily. The signs of toxicity and death of animals 
were recorded within the first ho�r after the administra-
tion of the st�dy dr�gs� then at �� 8 and �� ho�rs� and 
then for the next �� days with the administration of the 
st�dy dr�g. All mice living on the ��th day of the experi-
ment were e�thanized by dislocation of the cervix �nder 
anesthesia. To determine the LD5�� Kerber method was 
�sed [��]. To achieve greater acc�racy� six doses of the 
compositions �nder st�dy �6���6� mg/kg� were admin-
istered spaced by the same interval of �� mg/kg. Six 
series of experiments were cond�cted� with three gro�ps 
of animals �� mice each. LD��� val�e for each composi-
tion was determined with Taxotere �“Sanofi Aventis”�
being a reference dr�g. LD5� was then calc�lated �sing 
the form�la: 
LD50 = LD100 — Σ (Z • D)/m, 
where Z is the average n�mber of dead animals 
in two s�ccessive doses; D is the difference between 
two s�ccessive doses �dose interval�; m is the n�mber 
of animals in one gro�p. The statistical analysis was car-
ried o�t �sing MS Excel.
RESULTS AND DISCUSSION
Stability of Lip and s�bstance integration into Lip 
composition is infl�enced by ionic strength� pH val�e� 
temperat�re of technological process� time of every cycle� 
press�re� �ltraso�nd intensity� etc. It is important to �se 
specified concentration of b�ffer mixt�res� i.e. minimal 
salt concentration for b�ffer� allowing to maintain speci-
fied pH val�e. In o�r experiments� pH was shifted to the 
acidic range �by adding b�ffer mixt�re� for Doc stabiliza-
tion. Phase behavior of pH bilayer is determined by van 
der Waals interactions between neighboring molec�les 
of lipids in bilayer� which in t�rn depends on lipids packag-
ing in bilayer and chain length of fatty acid. Ph with longer 
“tails” have bigger area of interaction� which leads to the in-
crease of interaction force and th�s to lipid immobilization.
The choice of cryoprotectant� its concentration and 
form as well as the time-point of its �se in processing 
proced�re are essential factors for preparing Lip-incor-
porated compositions. Early s�pplementation with carbo-
hydrate cryoprotectant �for instance� lactose or trehalose� 
may be disadvantageo�s considering Lip size and de-
creased incorporation of active s�bstance. Also we have 
de monstrated that the more was amo�nt of s�gar �sed 
for nanoparticles protection d�ring lyophilization� the less 
was the increase in Lip size after rehydration.
The data on the efficacy of Doc incorporation into Lip 
at different ratios of components — membrane-b�ilding 
lipids� Doc and cryoprotectant �prior to and after lyophi-
lization� is presented in Table �. At a �:�5 Doc to Ph ratio� 
Doc incorporation into Lip amo�nts to 8��8�%. The 
increased amo�nt of lipids ��:�8��:��� res�lts in almost 
complete Doc incorporation into Lip. Meanwhile� Lip size 
in em�lsion samples practically does not depend on Doc 
to Ph ratio. More than 85% of nanoparticles were within 
the range of �����6� nm. We also noticed q�ite high rate 
of Doc incl�sion in lipid bilayer. It is also necessary to take 
into acco�nt the possibility direct interaction between 
Ph and Doc� which may res�lt in formation of the complex.
Table 1. Characteristics of Lip-Doc samples before and after lyophilization
Doc, 
mg
Ph, mg
PC:DPHG
Lac-
tose, 
mg
Doc: 
Ph
ratio
Doc in-
cor-
pora-
tion into 
Lip, %
Lip size, 
nm, be-
fore lyo-
philization
Doc
incorpora-
tion into Lip, 
%, after lyo-
philization
Lip size, 
nm, after 
lyophiliza-
tion
20 300
PC:DPHG 
270:30
300 1:15 80–87 95–160 80–85 120–180;300–500
20 350  
PC:DPHG
320:30
1050 1:18 > 97 100–160 95–97 120–160
20 400  
PC:DPHG
370:30
1600 1:20 > 98 100–150 95–98 100–160
Addition of negatively charged Ph� namely DPHG 
into Lip composition may be advantageo�s for Lip 
stabilization in processing proced�re as well as �pon 
rehydration of the lyophilized prod�ct with an aq�eo�s 
solvent. As seen from Table �� Lip size in lyophilized 
samples depends on the Doc to Ph ratio and on lipid 
s�bstance concentration. At �:�5 Doc to Ph ratio� two 
gro�ps of nanoparticles are formed �����8� nm �abo�t 
8�%� and ����5�� nm �abo�t ��%�. It is fair to ass�me 
that low lipid content of Lip res�lts in the release of a cer-
tain fraction of Doc from nanoparticles at lyophilization 
with accompanying formation of Lip with considerably 
larger size. Moreover� increase of Ph and cryoprotectant� 
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in partic�lar� PC and lactose in Lip sample composition� 
standardizes and stabilizes lipid particles after their re-
hydration. We have demonstrated that after lyophilization 
Lip size of dried samples remained �nchanged.
Using HPLC� we st�died Doc stability after Lip lyo-
philization. We confirmed the identity of q�antitative and 
q�alitative composition after drying and conseq�ent rehy-
dration of Lip samples. Imp�rity content and its retention 
time do not change� which may reflect Doc stability in the 
process of Lip preparation and their s�bseq�ent freeze-
drying; the content of imp�rities in lyophilized sampled did 
not exceed �.5%. The res�lts of stability st�dy of Lip Doc 
��-year storage below � °C� are given in Table �.
Table 2. Stability of Doc in liposomal form during storage
Characteristics 
of the drug*
Particle 
size, nm
Doc incor-
poration 
into Lip, %
Time of emul-
sion reconsti-
tution, min
рН
Impuri-
ties, % 
(HPLC)
The drug after 
preparation
100–160 > 95.0 NMT 3 5.45 2.3
The drug after 
2 years of storage
110–180 > 90.0 NMT 3 5.38 2.8
Note: * DPHG-Lip at a ratio of Doc:Ph — 1:20.
Therefore� the stability of the liposomal form of Doc 
was confirmed with Doc incorporation at the level of not 
less than ��% and Lip size of �����8� nm.
The toxicity of Lip samples containing Doc was 
compared with that of conventional dosage form of Doc 
�pon intraveno�s injection of the compositions �nder 
st�dy. We eval�ated LD5� of Lip form of Doc: containing 
DPHG �DPHG-Lip� at a �:�� ratio of Doc:Ph �see Table 
�� and a Lip form containing only PC �PC-Lip�. Red�c-
tion of toxicity of the liposomal form of Doc �LD5� ��� ± 
�.� mg/kg for DPGH-containing Lip� was fo�nd in com-
parison with its free form �LD5� ��� ± 6.� mg/kg� �p < �.��. 
We observed identical res�lts �sing liq�id and lyophilized 
forms� which proved stability of pharmacological proper-
ties of st�died compositions after lyophilization. Besides� 
it was de mon strated that PC increase in composition 
res�lted in the increase of n�mber of s�rvived mice while 
�sing Lip containing negatively charged lipid DPHG.
To s�m �p� a composition and a technological platform 
for creating a liposomal form of Doc have been proposed 
and a lyophilized preparation containing Doc� nat�ral 
phosphatidylcholine and diphosphatidyl glycerol has been 
obtained. As a cryoprotectant� disaccharide lactose was 
�sed. The particle size in nanosizes with the incorporation 
of Doc into the Lip being at least ��%. The dependence 
of LD5� on the composition of the dr�g was st�died. The 
stability of the dr�g was demonstrated within � years.
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